

75084335

75084335

75084335

75084335

Package leaflet: Information for the patient

Sitagliptin Mylan 25 mg film-coated tablets

Sitagliptin Mylan 50 mg film-coated tablets

Sitagliptin Mylan 100 mg film-coated tablets

sitagliptin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Sitagliptin Mylan is and what it is used for
2. What you need to know before you take Sitagliptin Mylan
3. How to take Sitagliptin Mylan
4. Possible side effects
5. How to store Sitagliptin Mylan
6. Contents of the pack and other information

1. What Sitagliptin Mylan is and what it is used for

Sitagliptin Mylan contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.

This medicine helps to increase the levels of insulin produced after a meal and decreases the amount of sugar made by the body.

Your doctor has prescribed this medicine to help lower your blood sugar, which is too high because of your type 2 diabetes. This medicine can be used alone or in combination with certain other medicines (insulin, metformin, sulphonylureas, or glitazones) that lower blood sugar, which you may already be taking for your diabetes together with a food and exercise plan.

What is type 2 diabetes?

Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.

2. What you need to know before you take Sitagliptin Mylan

Do not take Sitagliptin Mylan

- if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Sitagliptin Mylan (see section 4).

If you encounter blistering of the skin, it may be a sign for a condition called bullous pemphigoid.

Your doctor may ask you to stop Sitagliptin Mylan.

Tell your doctor if you have or have had:

- a disease of the pancreas (such as pancreatitis)
- gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.

These medical conditions can increase your chance of getting pancreatitis (see section 4).

- type 1 diabetes

- diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss,
- nausea or vomiting)
- any past or present kidney problems.
- an allergic reaction to Sitagliptin Mylan (see section 4).

This medicine is unlikely to cause low blood sugar because it does not work when your blood sugar is low. However, when this medicine is used in combination with a sulphonylurea medicine or with insulin, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your sulphonylurea or insulin medicine.

Children and adolescents

Children and adolescents below 18 years should not use this medicine. It is not effective in children and adolescents between the ages of 10 and 17 years. It is not known if this medicine is safe and effective when used in children younger than 10 years.

Other medicines and Sitagliptin Mylan

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heart beat and other heart problems). The level of digoxin in your blood may need to be checked if taking with Sitagliptin Mylan.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy.

It is not known if this medicine passes into breast milk. You should not take this medicine if you are breast-feeding or plan to breast-feed.

Driving and using machines

This medicine has no or negligible influence on the ability to drive and use machines. However, dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.

Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause hypoglycaemia, which may affect your ability to drive and use machines or work without safe foothold.

Sitagliptin Mylan contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium free'.

3. How to take Sitagliptin Mylan

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is:

- one 100 mg film-coated tablet
- once a day
- by mouth

If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).

You can take this medicine with or without food and drink.

Your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar.

Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and exercise recommended by your doctor while taking Sitagliptin Mylan.

If you take more Sitagliptin Mylan than you should

If you take more than the prescribed dosage of this medicine, contact your doctor immediately.

If you forget to take Sitagliptin Mylan

If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose to make up for a forgotten dose.

If you stop taking Sitagliptin Mylan

Continue to take this medicine as long as your doctor prescribes it so you can continue to help control your blood sugar. You should not stop taking this medicine without talking to your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

[Front Page #1]

Mylan				Date of Final	dd / mm / yy	Date of Issue	dd / mm / yy	Page Count	1 of 2
Date / Time of Creation	13/04/22 22:51	TrackWise / GLAMS ID	ART-23929-01	Client Market	United Kingdom	Software / Ver. No.	Adobe Indesign 2020		
Vendor Job No.	656335	Affiliate New Code	ART-23929-01	Product Description	LIT(B/F) SITAGLIPTIN MYLAN TAB (COMN) GB				
Artwork Proof No.	2	Superseded Code	NA	New Material Code	75084335	Actual A/w Size	180 x 320 mm (Open)		
Pharma Code	NA	Barcode Information	NA	ITF Barcode		Other Sizes (if any)	180 x 40 mm (Folded)		
Product Render ID No.	NA	MA Number	PL 04569/1811 , PL04569/1810 , PL04569/1809	Superseded Code	NIL	Pitch After Every	NA		
Main Font Type - 1	Myraid Pro	SAP or SPC Code	400560128, 400560127, 400560126	Component Type	Printed Literature	Eye / Sensor Mark	NA		
Main Font Type - 2	NA	Packaging Site	Mylan Laboratories Ltd. (Aurangabad - IN)	No. of Printed Colors	1	ITF Barcode Size	NA		
Reason for Revision / Issuance	New Component			Printed Colors CMYK / Pantone Colors Bridge Coated	<div style="background-color: black; color: white; padding: 2px;">BLACK</div>				
				Non Printed Colors	<div style="background-color: blue; color: white; padding: 2px;">Die Line</div>				
Artwork Implementation Schedule, (✓) whichever is applicable	New Component			Equivalent with CMYK (Pantone Ref. Codes)	NA				
	Immediately (Stock of superseded component to be destroyed, if applicable)			Material of Construction	40 gsm ITC Tribeni Paper				
	After Consumption of Existing (superseded) stock			Design & Style	Supply in Folded form as Proposed Size				
	Others (specify)			Prepared By	Checked By	Approved By			
Sign Offs	LABEL CONTROL / BUSINESS DEVELOPMENT / REGULATORY / MARKETING				Packaging Technical Services		Production	Regulatory Affairs	Quality Assurance
	Digital Signature	Digital Signature	Digital Signature	Digital Signature	Name Sign dd/mm/yy	Name Sign dd/mm/yy	Name Sign dd/mm/yy	Name Sign dd/mm/yy	Name Sign dd/mm/yy
Revision History	10/03/22-New Component			Date / Remarks	Date / Remarks	Date / Remarks	Format No.: SOP-000485364_FORM-000525810_Version-6.0		
	Date / Remarks			Date / Remarks	Date / Remarks	Date / Remarks			
	Date / Remarks			Date / Remarks	Date / Remarks	Date / Remarks			
	Date / Remarks			Date / Remarks	Date / Remarks	Date / Remarks			

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOP taking Sitagliptin Mylan and contact a doctor immediately if you notice any of the following serious side effects:

Severe and persistent pain in the abdomen (stomach area) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas (pancreatitis).

If you have a serious allergic reaction (frequency not known), including rash, hives, blisters on the skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing, stop taking this medicine and call your doctor right away. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.

Some patients have experienced the following side effects after adding sitagliptin to metformin:
Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting
Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness

Some patients have experienced different types of stomach discomfort when starting the combination of sitagliptin and metformin together (frequency is common).

Some patients have experienced the following side effects while taking sitagliptin in combination with a sulphonylurea and metformin:

Very common (may affect more than 1 in 10 people): low blood sugar
Common: constipation

Some patients have experienced the following side effects while taking sitagliptin and pioglitazone:
Common: flatulence, swelling of the hands or legs

Some patients have experienced the following side effects while taking sitagliptin in combination with pioglitazone and metformin:
Common: swelling of the hands or legs

Some patients have experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):
Common: flu
Uncommon: dry mouth

Some patients have experienced the following side effects while taking sitagliptin alone in clinical studies, or during post-approval use alone and/or with other diabetes medicines:

Common: low blood sugar, headache, upper respiratory infection, stuffy or runny nose and sore throat, osteoarthritis, arm or leg pain
Uncommon: dizziness, constipation, itching
Rare: reduced number of platelets
Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Sitagliptin Mylan

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister, bottle label and the carton after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Sitagliptin Mylan contains

- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 25 mg, sitagliptin.
- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg sitagliptin.
- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 100 mg sitagliptin.

The other ingredients are: In the tablet core: microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, calcium hydrogen phosphate and magnesium stearate. The tablet coating contains: poly(vinyl alcohol), macrogol, talc (E553b), titanium dioxide (E171), red iron oxide (E172) and yellow iron oxide (E172).

What Sitagliptin Mylan looks like and contents of the pack

Sitagliptin Mylan 25 mg film-coated tablets are round, biconvex pink film-coated tablet with M on one side and SL1 on the other side.

Sitagliptin Mylan 50 mg film-coated tablets are round, biconvex light brown film-coated tablet with M on one side and SL2 on the other side.

Sitagliptin Mylan 100 mg film-coated tablets round, biconvex brown film-coated tablet with M on one side and SL3 on the other side.

Sitagliptin Mylan 25 mg film-coated tablets are available in blisters (OPA/Alu/PVC//Alu) containing 14, 28, 30, 56 or 98 film-coated tablets or in OPA/Alu/PVC//Alu perforated unit dose blisters containing 14 x 1, 28 x 1 or 30 x 1 film-coated tablets or in calendar packs containing 28 film-coated tablets and in white plastic bottles with a white screw cap containing 98, 100 or 250 film-coated tablets.

Sitagliptin Mylan 50 mg film-coated tablets are available in blisters (OPA/Alu/PVC//Alu) containing 14, 28, 30, 56 or 98 film-coated tablets or in OPA/Alu/PVC//Alu perforated unit dose blisters containing 14 x 1, 28 x 1, 30 x 1, or 56 x 1 film-coated tablets or in calendar packs containing 28 film-coated tablets and in white plastic bottles with a white screw cap containing 98, 100 or 250 film-coated tablets.

Sitagliptin Mylan 100 mg film-coated tablets are available in blisters (OPA/Alu/PVC//Alu) containing 14, 30, 28, 56 or 98 film-coated tablets or in OPA/Alu/PVC//Alu perforated unit dose blisters containing 14 x 1, 28 x 1, 30 x 1, or 56 x 1 film-coated tablets or in calendar packs containing 28 film-coated tablets or 56 film-coated tablets and in white plastic bottles with a white screw cap containing 98, 100 or 250 film-coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Mylan,
Potters Bar,
EN6 1TL,
United Kingdom.

Manufacturer

Mylan Hungary Kft,
Mylan utca 1,
Komárom,
2900,
Hungary.

McDermott Laboratories Limited T/A Gerard Laboratories,
Unit 35/36 Baldoyle Industrial Estate,
Grange Road,
Dublin 13,
Ireland.




Medis International as,
Prumyslova 961/16, Bolatice,
747 23,
Czech Republic.

This leaflet was last revised in

February 2022

ART-23929-01
75084335

[Back Page #2]

				Date of Final	dd / mm / yy	Date of Issue	dd / mm / yy	Page Count	2 of 2
Date / Time of Creation	13/04/22 22:51	TrackWise / GLAMS ID	ART-23929-01	Client Market	United Kingdom	Software / Ver. No.	Adobe Indesign 2020		
Vendor Job No.	656335	Affiliate New Code	ART-23929-01	Product Description	LIT(B/F) SITAGLIPTIN MYLAN TAB (COMN) GB				
Artwork Proof No.	2	Superseded Code	NA	New Material Code	75084335	Actual A/w Size	180 x 320 mm (Open)		
Pharma Code	NA	Barcode Information	NA	ITF Barcode		Other Sizes (if any)	180 x 40 mm (Folded)		
Product Render ID No.	NA	MA Number	PL 04569/1811, PL04569/1810, PL04569/1809	Superseded Code	NIL	Pitch After Every	NA		
Main Font Type - 1	Myraid Pro	SAP or SPC Code	400560128, 400560127, 400560126	Component Type	Printed Literature	Eye / Sensor Mark	NA		
Main Font Type - 2	NA	Packaging Site	Mylan Laboratories Ltd. (Aurangabad - IN)	No. of Printed Colors	1	ITF Barcode Size	NA		
Reason for Revision / Issuance	New Component			Printed Colors CMYK / Pantone Colors Bridge Coated					
				Non Printed Colors					
Artwork Implementation Schedule, (✓) whichever is applicable	New Component			Equivalent with CMYK (Pantone Ref. Codes)	NA				
	Immediately (Stock of superseded component to be destroyed, if applicable)			Material of Construction	40 gsm ITC Tribeni Paper				
	After Consumption of Existing (superseded) stock				Design & Style				
	Others (specify)				Supply in Folded form as Proposed Size				
LABEL CONTROL / BUSINESS DEVELOPMENT / REGULATORY / MARKETING				Prepared By	Checked By	Approved By			
Sign Offs	Digital Signature	Digital Signature	Digital Signature	Packaging Technical Services		Production	Regulatory Affairs	Quality Assurance	
				Name Sign dd/mm/yy	Name Sign dd/mm/yy	Name Sign dd/mm/yy	Name Sign dd/mm/yy	Name Sign dd/mm/yy	
Revision History	10/03/22-New Component			Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks		Format No.: SOP-000485364_FORM-000525810_Version-6.0			

75088900



Package leaflet: Information for the patient
Sitagliptin Mylan 25 mg
film-coated tablets
Sitagliptin Mylan 50 mg
film-coated tablets
Sitagliptin Mylan 100 mg
film-coated tablets
 sitagliptin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Sitagliptin Mylan is and what it is used for
2. What you need to know before you take Sitagliptin Mylan
3. How to take Sitagliptin Mylan
4. Possible side effects
5. How to store Sitagliptin Mylan
6. Contents of the pack and other information

1. What Sitagliptin Mylan is and what it is used for

Sitagliptin Mylan contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.

This medicine helps to increase the levels of insulin produced after a meal and decreases the amount of sugar made by the body.

Your doctor has prescribed this medicine to help lower your blood sugar, which is too high because of your type 2 diabetes. This medicine can be used alone or in combination with certain other medicines (insulin, metformin, sulphonylureas, or glitazones) that lower blood sugar, which you may already be taking for your diabetes together with a food and exercise plan.

What is type 2 diabetes?

Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.

2. What you need to know before you take Sitagliptin Mylan

Do not take Sitagliptin Mylan:

- if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Sitagliptin Mylan (see section 4).

If you encounter blistering of the skin, it may be a sign for a condition called bullous pemphigoid.

Your doctor may ask you to stop Sitagliptin Mylan.

Tell your doctor if you have or have had:

- a disease of the pancreas (such as pancreatitis)
- gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.

These medical conditions can increase your chance of getting pancreatitis (see section 4):

- type 1 diabetes
- diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss,
- nausea or vomiting)
- any past or present kidney problems.
- an allergic reaction to Sitagliptin Mylan (see section 4).

This medicine is unlikely to cause low blood sugar because it does not work when your blood sugar is low. However, when this medicine is used in combination with a sulphonylurea medicine or with insulin, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your sulphonylurea or insulin medicine.

Children and adolescents

Children and adolescents below 18 years should not use this medicine. It is not effective in children and adolescents between the ages of 10 and 17 years. It is not known if this medicine is safe and effective when used in children younger than 10 years.

Other medicines and Sitagliptin Mylan

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heart beat and other heart problems). The level of digoxin in your blood may need to be checked if taking with Sitagliptin Mylan.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

You should not take this medicine during pregnancy.

It is not known if this medicine passes into breast milk. You should not take this medicine if you are breast-feeding or plan to breast-feed.

Driving and using machines

This medicine has no or negligible influence on the ability to drive and use machines. However, dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.

Taking this medicine in combination with medicines called sulphonylureas or with insulin can cause hypoglycaemia, which may affect your ability to drive and use machines or work without safe foothold.

Sitagliptin Mylan contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium free'.

3. How to take Sitagliptin Mylan

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is:

- one 100 mg film-coated tablet
- once a day
- by mouth

If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg). You can take this medicine with or without food and drink.

Your doctor may prescribe this medicine alone or with certain other medicines that lower blood sugar.

Diet and exercise can help your body use its blood sugar better. It is important to stay on the diet and exercise recommended by your doctor while taking Sitagliptin Mylan.

If you take more Sitagliptin Mylan than you should

If you take more than the prescribed dosage of this medicine, contact your doctor immediately.

If you forget to take Sitagliptin Mylan

If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take a double dose to make up for a forgotten dose.

If you stop taking Sitagliptin Mylan

Continue to take this medicine as long as your doctor prescribes it so you can continue to help control your blood sugar. You should not stop taking this medicine without talking to your doctor first. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


center fold

75088900



center fold

75088900



75088900



[Page # 1 of 2]

Mylan				Date of Final	dd / mm / yy	Date of Issue	dd / mm / yy	Page Count	1 of 2	
Date/Time of Creation	20/04/22 18:58	Track-Wise PR No.	ART-23537-01	Client Market	United Kingdom	Software / Ver. No.	Adobe Indesign 2020			
Vendor Job No.	657716	Affiliate New Code	ART-23537-01	Product Description	LIT(B/F)SITAGLIPTIN MY TAB(COM-HNG)GB					
Artwork Proof No.	3	Aff. Superseded Code	NA	New Material Code	75088900	Actual A/w Size	Open Size - 180 x 480 mm			
Pharma Code	NA	Barcode Information	NA	ITF Barcode		Other Sizes (if any)	Folded size - 180 x 240 mm			
Product Render ID No.	NA	MA Number	PL 04569/1809, PL 04569/1810, PL 04569/1811	Superseded Code	NIL	Pitch After Every	NA			
Main Font Type - 1	Myriad Pro	SAP or SPC Code	400560126, 400560127, 400560128	Component Type	Printed Literature	Eye / Sensor Mark	NA			
Main Font Type - 2	NA	Packaging Site	Mylan Laboratories Ltd., FDP 3 (Pitampur, Dhar Dist., M.P. - IN)	No. of Printed Colors	1	ITF Barcode Size	NA			
Min. Font Size	11 pt	Mfg. Lic. No. / Code No.	NA	Printed Colors CMYK / PMS Coated / PMS Color Bridge Coated	<table border="1"> <tr> <td>BLACK</td> </tr> </table>					BLACK
BLACK										
Reason for Revision / Issuance	New Component			Non Printed Colors	<table border="1"> <tr> <td>Die Line</td> </tr> </table>					Die Line
Die Line										
Artwork Implementation Schedule, (✓) whichever is applicable	New Component			Equivalent with CMYK (Pantones Ref. Code)	NA					
	Immediately (Stock of superseded component to be destroyed, if applicable)			Material of Construction	40 gsm ITC Tribeni Paper					
	After Consumption of Existing (superseded) stock			Design & Style	Supply Leaflet in Folded Form as Proposed Size					
	Others (specify)			Prepared By	Checked By	Approved By				
Sign Offs	LABEL CONTROL / BUSINESS DEVELOPMENT / REGULATORY / MARKETING				Packaging Technical Services		Production	Regulatory Affairs	Quality Assurance	
	Digital Signature	Digital Signature	Digital Signature	Digital Signature						
Revision History	16.03.2022 - KLD SHARED			Date / Remarks	Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks	Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks	Date / Remarks		Date / Remarks			

75088900

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

STOP taking Sitagliptin Mylan and contact a doctor immediately if you notice any of the following serious side effects:

Severe and persistent pain in the abdomen (stomach area) which might reach through to your back with or without nausea and vomiting, as these could be signs of an inflamed pancreas (pancreatitis).

If you have a serious allergic reaction (frequency not known), including rash, hives, blisters on the skin/peeling skin and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing, stop taking this medicine and call your doctor right away. Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes.

Some patients have experienced the following side effects after adding sitagliptin to metformin:

Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting

Uncommon (may affect up to 1 in 100 people): stomach ache, diarrhoea, constipation, drowsiness

Some patients have experienced different types of stomach discomfort when starting the combination of sitagliptin and metformin together (frequency is common).

Some patients have experienced the following side effects while taking sitagliptin in combination with a sulphonylurea and metformin:

Very common (may affect more than 1 in 10 people): low blood sugar

Common: constipation

Some patients have experienced the following side effects while taking sitagliptin and pioglitazone:

Common: flatulence, swelling of the hands or legs

Some patients have experienced the following side effects while taking sitagliptin in combination with pioglitazone and metformin:

Common: swelling of the hands or legs

Some patients have experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):

Common: flu

Uncommon: dry mouth

Some patients have experienced the following side effects while taking sitagliptin alone in clinical studies, or during post-approval use alone and/or with other diabetes medicines:

Common: low blood sugar, headache, upper respiratory infection, stuffy or runny nose and sore throat, osteoarthritis, arm or leg pain

Uncommon: dizziness, constipation, itching

Rare: reduced number of platelets

Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Sitagliptin Mylan

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister, bottle label and the carton after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Sitagliptin Mylan contains:

- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 25 mg, sitagliptin.
- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg sitagliptin.
- The active substance is sitagliptin. Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 100 mg sitagliptin.

The other ingredients are: In the tablet core: microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, calcium hydrogen phosphate and magnesium stearate. The tablet coating contains: poly(vinyl alcohol), macrogol, talc (E553b), titanium dioxide (E171), red iron oxide (E172) and yellow iron oxide (E172).

What Sitagliptin Mylan looks like and contents of the pack

Sitagliptin Mylan 25 mg film-coated tablets are round, biconvex pink film-coated tablet with M on one side and SL1 on the other side.

Sitagliptin Mylan 50 mg film-coated tablets are round, biconvex light brown film-coated tablet with M on one side and SL2 on the other side.

Sitagliptin Mylan 100 mg film-coated tablets are round, biconvex brown film-coated tablet with M on one side and SL3 on the other side.

Sitagliptin Mylan 25 mg film-coated tablets are available in blisters (OPA/Alu/PVC//Alu) containing 14, 28, 30, 56 or 98 film-coated tablets or in OPA/Alu/PVC//Alu perforated unit dose blisters containing 14 x 1, 28 x 1 or 30 x 1 film-coated tablets or in calendar packs containing 28 film-coated tablets and in white plastic bottles with a white screw cap containing 98, 100 or 250 film-coated tablets.

Sitagliptin Mylan 50 mg film-coated tablets are available in blisters (OPA/Alu/PVC//Alu) containing 14, 28, 30, 56 or 98 film-coated tablets or in OPA/Alu/PVC//Alu perforated unit dose blisters containing 14 x1, 28 x 1, 30 x 1, or 56 x 1 film-coated tablets or in calendar packs containing 28 film-coated tablets and in white plastic bottles with a white screw cap containing 98, 100 or 250 film-coated tablets.

Sitagliptin Mylan 100 mg film-coated tablets are available in blisters (OPA/Alu/PVC//Alu) containing 14, 30, 28, 56 or 98 film-coated tablets or in OPA/Alu/PVC//Alu perforated unit dose blisters containing 14 x 1, 28 x 1, 30 x 1, or 56 x 1 film-coated tablets or in calendar packs containing 28 film-coated tablets or 56 film-coated tablets and in white plastic bottles with a white screw cap containing 98, 100 or 250 film-coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Mylan,
Potters Bar,
EN6 1TL,
United Kingdom.

Manufacturer

Mylan Hungary Kft,
Mylan utca 1,
Komárom,
2900,
Hungary.

McDermott Laboratories Ltd T/A Gerard Laboratories,
Unit 35/36 Baldoyle Industrial Estate,
Grange Road,
Dublin 13,
Ireland.

Medis International as,
Prumyslova 961/16,
Bolatice, 747 23,
Czech Republic.

This leaflet was last revised in

February 2022

ART-23537-01
75088900

[Page # 2 of 2]

Mylan				Date of Final	dd / mm / yy	Date of Issue	dd / mm / yy	Page Count	2 of 2
Date/Time of Creation	20/04/22 18:58	Track-Wise PR No.	ART-23537-01	Client Market	United Kingdom	Software / Ver. No.	Adobe Indesign 2020		
Vendor Job No.	657716	Affiliate New Code	ART-23537-01	Product Description	LIT(B/F)SITAGLIPTIN MY TAB(COM-HNG)GB				
Artwork Proof No.	3	Aff. Superseded Code	NA						
Pharma Code	NA	Barcode Information	NA	New Material Code	75088900	Actual A/w Size	Open Size - 180 x 480 mm		
Product Render ID No.	NA	MA Number	PL 045691809, PL 045691810, PL 045691811	ITF Barcode		Other Sizes (if any)	Folded size - 180 x 240 mm		
Main Font Type - 1	Myriad Pro	SAP or SPC Code	400560126, 400560127, 400560128	Superseded Code	NIL	Pitch After Every	NA		
Main Font Type - 2	NA	Packaging Site	Mylan Laboratories Ltd., FDF 3 (Pitampur, Dhar Dist., M.P. - IN)	Component Type	Printed Literature	Eye / Sensor Mark	NA		
Min. Font Size	11 pt	Mfg. Lic. No. / Code No.	NA	No. of Printed Colors	1	ITF Barcode Size	NA		
Reason for Revision / Issuance	New Component			Printed Colors CMYK / PMS Coated / PMS Color Bridge Coated	BLACK				
	NA			Non Printed Colors	Die Line				
	NA			Equivalent with CMYK (Pantones Ref. Code)	NA				
Artwork Implementation Schedule, (✓) whichever is applicable	New Component			Material of Construction	40 gsm ITC Tribeni Paper				
	Immediately (Stock of superseded component to be destroyed, if applicable)								
	After Consumption of Existing (superseded) stock			Design & Style	Supply Leaflet in Folded Form as Proposed Size				
	Others (specify)								
LABEL CONTROL / BUSINESS DEVELOPMENT / REGULATORY / MARKETING				Prepared By	Checked By	Approved By			
Sign Offs				Packaging Technical Services		Production	Regulatory Affairs	Quality Assurance	
	Digital Signature	Digital Signature	Digital Signature	Digital Signature					
Revision History	16.03.2022 - KLD SHARED			Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks		Date / Remarks			
	Date / Remarks			Date / Remarks		Date / Remarks			